Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: Int J Parasitol. 2010 Jul 8;40(13):1549–1561. doi: 10.1016/j.ijpara.2010.05.011

Fig. 6 — The immunological efficacy of a triple virus vector vaccination regimen using three different recombinant viruses. B6 mice were primed with 4 × 10⁴ plaque forming units (PFU) of either recombinant influenza (re-FLU) or control FLU. Fourteen days later, the mice were immunized with 5 × 10⁸ PFU of either recombinant adenovirus (re-Ad) or control Ad. Then, 14 days after the first booster immunization, mice were given a second booster immunzation with either 5 × 10⁸ PFU of recombinant vaccinia virus (re-MVA) or 5 × 10⁸ PFU of control MVA. Each experimental group includes six to 10 mice. They were infected with 5,000 (A), 1,000 (B) or 100 (C) of Tulahuen strain of Trypanosoma cruzi blood-form trypomastigotes 14 days (A) or 21 days (B, C) after the last immunization. The number of parasites in 5 μl of peripheral blood (parasitemia) was counted at 10, 14, 21, 28, 35, 42 and 49 days p.i. *, P < 0.05 and **, P < 0.01 determined by the Student's t-test compared with the parasitemia of FLU/Ad/MVA-immunized mice. Survival was monitored daily. (A) The survival of re-FLU/re-Ad/re-MVA-immunized mice (●) was significantly different compared with either the survival of FLU/re-Ad/re-MVA-immunized mice (○) (P < 0.05) or the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01). The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.05). (B) The survival of re-FLU/re-Ad/re-MVA-immunized mice (●) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01). The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.05). (C) All of the re-FLU/re-Ad/re-MVA-immunized mice (●) survived the T. cruzi infection. The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01).

Fig. 6 — The immunological efficacy of a triple virus vector vaccination regimen using three different recombinant viruses. B6 mice were primed with 4 × 10⁴ plaque forming units (PFU) of either recombinant influenza (re-FLU) or control FLU. Fourteen days later, the mice were immunized with 5 × 10⁸ PFU of either recombinant adenovirus (re-Ad) or control Ad. Then, 14 days after the first booster immunization, mice were given a second booster immunzation with either 5 × 10⁸ PFU of recombinant vaccinia virus (re-MVA) or 5 × 10⁸ PFU of control MVA. Each experimental group includes six to 10 mice. They were infected with 5,000 (A), 1,000 (B) or 100 (C) of Tulahuen strain of Trypanosoma cruzi blood-form trypomastigotes 14 days (A) or 21 days (B, C) after the last immunization. The number of parasites in 5 μl of peripheral blood (parasitemia) was counted at 10, 14, 21, 28, 35, 42 and 49 days p.i. *, P < 0.05 and **, P < 0.01 determined by the Student's t-test compared with the parasitemia of FLU/Ad/MVA-immunized mice. Survival was monitored daily. (A) The survival of re-FLU/re-Ad/re-MVA-immunized mice (●) was significantly different compared with either the survival of FLU/re-Ad/re-MVA-immunized mice (○) (P < 0.05) or the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01). The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.05). (B) The survival of re-FLU/re-Ad/re-MVA-immunized mice (●) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01). The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.05). (C) All of the re-FLU/re-Ad/re-MVA-immunized mice (●) survived the T. cruzi infection. The survival of FLU/re-Ad/re-MVA-immunized mice (○) was significantly different compared with the survival of FLU/Ad/MVA-immunized mice (△) (P < 0.01).